Esomeprazole potassium - CAS 161796-84-5
Catalog number: 161796-84-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Proton Pump
Esomeprazole potassium is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or ameliorates peptic ulcer or irritation of the gastrointestinal tract.
White crystalline powder
potassium;5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-ide AstraZeneca Brand of Esomeprazole Magnesium Esomeprazole Esomeprazole Magnesium Esomeprazole Potassium Esomeprazole Sodium Esomeprazole Strontium Esomeprazole
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -31℃ for long term (months to years).
Shelf Life:
2 years
Canonical SMILES:
1.The Protective Effects of 18β-Glycyrrhetinic Acid on Helicobacter pylori-Infected Gastric Mucosa in Mongolian Gerbils.
Cao D1, Jiang J1, You L1, Jia Z1, Tsukamoto T2, Cai H3, Wang S3, Hou Z3, Suo YE3, Cao X3. Biomed Res Int. 2016;2016:4943793. doi: 10.1155/2016/4943793. Epub 2016 Feb 24.
18β-Glycyrrhetinic acid (GRA), a major component of Glycyrrhiza glabra, is widely used therapeutically in clinic. In this study, the effect of GRA on Helicobacter pylori- (H. pylori-) infected gastritis was investigated in Mongolian gerbils in vivo. The gerbils were randomly divided into groups: uninfected; H. pylori-infected; H. pylori + antibiotics (clarithromycin, amoxicillin, and esomeprazole); and H. pylori + GRA. The gastric intraluminal pH value, histopathological changes, and the expression levels of inflammation-related cytokines (IL-1β, TNF-α, COX-2, and iNOS) were investigated. The results showed that, in the H. pylori + GRA group, the intraluminal gastric pH value was lower (2.14 ± 0.08 versus 3.17 ± 0.23, P < 0.05), erosion and hyperplasia were alleviated, the infiltration of neutrophils and mononuclear cells was attenuated (P < 0.05), and the expression levels of TNF-α, IL-1β, COX-2, and iNOS were decreased (P < 0.
2.Role of Quantitative Clinical Pharmacology in Pediatric Approval And Labeling.
Mehrotra N1, Bhattaram A2, Earp JC2, Florian J2, Krudys K2, Lee JE2, Lee JY2, Liu J2, Mulugeta Y2, Yu J2, Zhao P2, Sinha V2. Drug Metab Dispos. 2016 Apr 14. pii: dmd.116.069559. [Epub ahead of print]
Dose selection is one of the key decisions made during the drug development in pediatrics. There are regulatory initiatives that promote the use of model based drug development in pediatrics. Pharmacometrics or quantitative clinical pharmacology enables development of models that can describe factors affecting pharmacokinetics and/or pharmacodynamics in pediatric patients. This manuscript describes some of the examples where pharmacometric analysis was utilized to support approval and labeling in pediatrics. In particular, the role of pharmacokinetic comparison of pediatric PK to adults and utilization of dose/exposure-response analysis for dose selection is highlighted. Dose selection for esomeprazole in pediatrics was based on PK matching to adults while for adalimumab, exposure-response, PK, efficacy and safety data together was useful to recommend doses for pediatric crohn's disease. For vigabatrin, demonstration of similar dose-response between pediatrics and adults allowed for selection of a pediatric dose.
3.[In vitro susceptibility of Trichomonas vaginalis to metronidazole, ornidazole and proton pump inhibitors pantoprazole and esomeprazole].
Aksoy Gökmen A1, Girginkardeşler N, Kilimcioğlu AA, Şirin MC, Özbilgin A. Mikrobiyol Bul. 2016 Jan;50(1):133-9.
The current treatment of trichomoniasis is based on the use of 5-nitroimidazole derivatives. Although metronidazole is reliable, inexpensive and highly effective against anaerobic microorganisms and protozoa, the development of metronidazole-resistant T.vaginalis strains pose to an increasing problem. Nitroimidazoles are compounds having azomycin (2-nitroimidazole) chemical structure and are obtained from Streptomyces strains. Benzimidazole, which is found in the structure of proton pump inhibitors, is also present in the other components that have antiprotozoal activity. In this study, the in vitro susceptibility of T.vaginalis against metronidazole, ornidazole, and the proton pump inhibitors which are tested recently as antiprotozoal agents; pantoprazole and esomeprazole was investigated. For this purpose a clinical T.vaginalis strain which was formerly isolated and stored after cryopreservation process in our laboratory was used. Minimum inhibitory concentration (MIC) and minimum lethal concentration (MLC) values of those agents against to this strain were determined in vitro by dilution method in 24-well cell culture plates.
4.Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and Acid Regurgitation Symptoms in Individuals Taking Esomeprazole 20 mg or Placebo.
Johnson DA1, Le Moigne A2, Li J2, Pollack C2, Nagy P3. Clin Drug Investig. 2016 Apr 13. [Epub ahead of print]
BACKGROUND AND OBJECTIVE: Sleep disturbances related to reflux symptoms have a significant impact on the daily lives of affected individuals. These analyses identified clinical factors related to resolution of reflux-related sleep disturbance in subjects treated with esomeprazole 20 mg for 14 days.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Proton Pump Products

CAS 135779-82-7 Bamaquimast

(CAS: 135779-82-7)

Bamaquimast is an orally active inhibitor of proton pump with anti-inflammatory and antiasthmatic effects.

CAS 117976-90-6 Rabeprazole Sodium

Rabeprazole Sodium
(CAS: 117976-90-6)

The sodium salt form of Rabeprazole which is a partially reversible inhibitor of gastric proton pump and could be used in the treatment of sorts of gastrointest...

Esomeprazole magnesium salt
(CAS: 1198768-91-0)

The magnesium salt form of Esomeprazole which is a proton pump inhibitor so that could be probably useful in the treatment of sorts of digestive tract diseases ...

CAS 103577-45-3 Lansoprazole.

(CAS: 103577-45-3)

Lansoprazole is a proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.

CAS 164579-32-2 Pantoprazole sodium hydrate

Pantoprazole sodium hydrate
(CAS: 164579-32-2)

Pantoprazole sodium hydrate is a proton pump inhibitor which acts as selective inhibiton of H+/K+-ATPase. With antiulcerative effects in vivo, it treats or amel...

Lansoprazole sodium
(CAS: 226904-00-3)

Lansoprazole sodium is the sodium salt form of Lansoprazole. Lansoprazole, a substituted benzimidizole, is proton pump inhibitor, is a proton pump inhibitor whi...

CAS 102625-70-7 Pantoprazole

(CAS: 102625-70-7)

Pantoprazole, an irreversible protonpump inhibitor, inhibits the final step of the production ofgastric acid by binding to the sites of H+/K+ ATPase system in g...

CAS 261944-46-1 Soraprazan

(CAS: 261944-46-1)

Soraprazan, also known as BY359, is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase, used as anti-secretory drug.

Chemical Structure

CAS 161796-84-5 Esomeprazole potassium

Quick Inquiry

Verification code

Featured Items